News Releases

Oct 01, 2021
SHANGHAI and GAITHERSBURG, Md. , Oct. 1, 2021 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in
Sep 13, 2021
SHANGHAI and GAITHERSBURG, Md. , Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG
Sep 02, 2021
SHANGHAI and GAITHERSBURG, Md. , Sept. 2, 2021 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global
Aug 30, 2021
SHANGHAI and GAITHERSBURG, Md. , Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in
Displaying 1 - 10 of 49